FDA Approves First Generic Single-Dose Flu Medication

The U.S. FDA has approved the first generic version of baloxavir marboxil, a single-dose treatment for acute uncomplicated influenza and post-exposure prophylaxis. Developed by Norwich Pharmaceuticals, this approval aims to enhance affordability and accessibility of flu treatment. It comes ahead of the 2026-2027 flu season, offering a new option for patients aged 5 and older.